Who
James Gordon Liddy
Director
Company insider
Files Form 4 as: Director, Hepion Pharmaceuticals; Director, Canton Strategic Holdings.
In numbers
- Trades disclosed
- 3
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 3 Nov 2025
- Last trade
- 19 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 21 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —299,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —299,000 at $0.00 | filing |
| 3 Nov 2025filed 5 Nov 2025 | CNTN Canton Strategic Holdingsoption or derivative · Digital Asset Treasuries | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.